{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:42:08Z","timestamp":1679028128126},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1672","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the intravenously administered synthetic vasopressin analog terlipressin (Terlivaz \u2013 Mallinckrodt) to improve kidney function in adults with hepatorenal syndrome (HRS) and a rapid decline in kidney function. Terlipressin is the first drug to be approved for this indication in the US; it has been available in Europe and elsewhere for years.<\/jats:p>","DOI":"10.58347\/tml.2023.1672c","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:23:07Z","timestamp":1678980187000},"page":"46-48","source":"Crossref","is-referenced-by-count":0,"title":["Terlipressin (Terlivaz) for Hepatorenal Syndrome"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,3,20]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:23:07Z","timestamp":1678980187000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1672c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":0,"journal-issue":{"issue":"1672","published-online":{"date-parts":[[2023,3,20]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1672c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]}}}